Adma Biologics reported $26.74M in Selling and Administration Expenses for its fiscal quarter ending in March of 2026.





Selling And Administration Expenses Change Date
Adma Biologics USD 26.74M 6.55M Mar/2026
Alnylam Pharmaceuticals USD 347.92M 65.41M Jun/2026
BioCryst Pharmaceuticals USD 63.98M 31.8M Jun/2026
Minerva Neurosciences USD 2.48M 58.79K Sep/2024
Novavax USD 25.53M 1.34M Dec/2025
Omeros USD 11.32M 2.48M Sep/2024
Takeda JPY 286.51B 5.48B Jun/2026